Veselin Mitrovic

Veselin Mitrovic

Auto-generated profile, based on publicly available information

Veselin Mitrovic

Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2017 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
CTCristina Tita
Cristina Tita
EGEdward M. Gilbert
Edward M. Gilbert
ABAdrian B. Van Bakel
Adrian B. Van Bakel
JGJacek Grzybowski
Jacek Grzybowski
GHGarrie J. Haas
Garrie J. Haas
VMVeselin Mitrovic
Veselin Mitrovic
Aims This study was designed to evaluate the safety, tolerability and haemodynamic effects of BMS‐986231, a novel second‐generation nitroxyl donor with potential inotropic, lusitropic and vasodilatory effects in patients hospitalized with decompensated heart failure and reduced ejection fraction (HFrEF). Methods and results Forty‐six patients hospitalized with decompensated HFrEF were enrolled into four sequential dose‐escalation cohorts in this double‐blind, randomized, placebo‐controlled Phase 2a study. Patients with baseline pulmonary capillary wedge pressure (PCWP) of ≥20 mmHg and a cardiac index of ≤2.5 L/min/m2 received one 6‐h i.v. infusion of BMS‐986231 (at 3, 5, 7 or 12 µg/kg/min) or placebo. BMS‐986231 produced rapid and sustained reductions in PCWP, as well as consistent reductions in time‐averaged pulmonary arterial systolic pressure, pulmonary arterial diastolic pressure and right atrial pressure. BMS‐986231 increased non‐invasively measured time‐averaged stroke volume index, cardiac index and cardiac power index values, and decreased total peripheral vascular resistance. There was no evidence of increased heart rate, drug‐related arrhythmia or symptomatic hypotension with BMS‐986231. Analyses of adverse events throughout the 30‐day follow‐up did not identify any toxicities specific to BMS‐986231, with the potential exception of infrequent mild‐to‐moderate headaches during infusion. There were no treatment‐related serious adverse events. Conclusions BMS‐986231 demonstrated a favourable safety and haemodynamic profile in patients hospitalized with advanced heart failure. Based on preclinical data and these study's findings, it is possible that the haemodynamic benefits may be mediated by inotropic and/or lusitropic as well as vasodilatory effects. The therapeutic potential of BMS‐986231 should be further assessed in patients with heart failure.

1 July 2009 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
VMVeselin Mitrovic
Veselin Mitrovic
AHAdrian F. Hernandez
Adrian F. Hernandez
MMMarkus Meyer
Markus Meyer
MGMihai Gheorghiade
Mihai Gheorghiade

1 March 2006 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
MBM. Burian
M. Burian
TNT. Neumann
T. Neumann
MWM. Weber
M. Weber
RBR. Brandt
R. Brandt
GGG. Geisslinger
G. Geisslinger
CHC. Hamm
C. Hamm
The present study was undertaken to evaluate the safety and release of nickel after implantation of a nickel device (Amplatzer occluder) in patients with an atrial septal defect (ASD) receiving antiplatelet therapy. Blood and urine samples were obtained from 24 patients with ASD before occluder implantation (baseline) and during a 12-month post closure period. Antiplatelet drugs were administered for the initial 6-month period post implantation. The nickel content in the specimens was determined using electrothermal atomic absorption spectroscopy. The clinical, sonographic and magnetic resonance imaging follow-ups were carried out 1 week, 1 month, 6 months and 12 months post implantation. Mean baseline concentrations of nickel in serum and urine were within normal range with values of 0.6 +/- 0.2 microg/l and 3.1 +/- 1.2 microg/l, respectively. During the 6-week post closure period, the time needed for the formation of neointima on the surface of the graft, nickel levels in serum increased up to 5-fold (p < 0.01 versus baseline). Mean concentrations in serum and urine returned to baseline levels within 4-6 months post implantation. All patients showed satisfactory clinical improvements and there was no sonographic evidence of complications. The initial dissolution of nickel from the Amplatzer occluder is not a specific cardiovascular risk and is temporarily linked to the formation of the non-thrombogenic neointima on the surface of the graft. The antiplatelet drug regimen used (300 mg aspirin + 75 mg clopidogrel daily for 3 months in the initial phase and 100 mg aspirin daily for a further 3 months) appears to cover the period of neointima formation on the nickel device when nickel levels are significantly elevated. However, further studies in a larger number of patients and over a period greater than 12 months are needed to confirm the validity of these conclusions and to formulate definitive recommendations on the duration of the antiplatelet treatment.

5 January 2011 in Current Heart Failure Reports
Verified
Journal Article
Open access
PDF file
VMVeselin Mitrovic
Veselin Mitrovic
AJAna Jovanovic
Ana Jovanovic
SLStefan Lehinant
Stefan Lehinant
This review summarizes the role of soluble guanylate cyclase (sGC)-cyclic guanosine 3′, 5′-monophosphate pathways in heart failure and several new drugs that modify guanylate cyclase. The sGC activators and stimulators as modulators of sGC are promising drugs in the therapy for decompensated heart failure and pulmonary hypertension. Cinaciguat is a nitric oxide (NO)–independent direct activator of sGC, which also may be effective under oxidative stress conditions resulting in oxidized or heme-free sGC refractory to organic nitrates. Riociguat is an NO-independent direct stimulator of sGC with beneficial effects in patients with decompensated heart failure and pulmonary hypertension. The sGC modulators play an important role in patients with heart failure and pulmonary hypertension.

1 May 2005 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
VMV. Mitrovic
V. Mitrovic
HKH. H. Klein
H. H. Klein
NKN. Krekel
N. Krekel
JKJ. Kreuzer
J. Kreuzer
SFS. Fichtlscherer
S. Fichtlscherer
CHC. W. Hamm
C. W. Hamm

11 August 2009 in BMC Pharmacology
Verified
Journal Article
Open access
PDF file
VMVeselin Mitrovic
Veselin Mitrovic
BSB Swidnicki
B Swidnicki
HGHossein Ardeschir Ghofrani
Hossein Ardeschir Ghofrani
WMWolfgang Mück
Wolfgang Mück
NKNina Kirschbaum
Nina Kirschbaum
SLSilvia Lentini
Silvia Lentini